Eli Lilly and Co (LLY)
729.00
-16.95
(-2.27%)
USD |
NYSE |
Apr 19, 14:13
Eli Lilly Research and Development Expense (TTM): 9.313B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 9.313B |
September 30, 2023 | 8.747B |
June 30, 2023 | 8.140B |
March 31, 2023 | 7.566B |
December 31, 2022 | 7.191B |
September 30, 2022 | 7.093B |
June 30, 2022 | 6.996B |
March 31, 2022 | 6.869B |
December 31, 2021 | 6.931B |
September 30, 2021 | 6.870B |
June 30, 2021 | 6.630B |
March 31, 2021 | 6.366B |
December 31, 2020 | 6.086B |
September 30, 2020 | 5.829B |
June 30, 2020 | 5.745B |
March 31, 2020 | 5.757B |
December 31, 2019 | 5.595B |
September 30, 2019 | 5.405B |
June 30, 2019 | 5.305B |
March 31, 2019 | 5.174B |
December 31, 2018 | 5.051B |
September 30, 2018 | 4.885B |
June 30, 2018 | 4.944B |
March 31, 2018 | 4.945B |
December 31, 2017 | 5.096B |
Date | Value |
---|---|
September 30, 2017 | 5.387B |
June 30, 2017 | 5.284B |
March 31, 2017 | 5.348B |
December 31, 2016 | 5.310B |
September 30, 2016 | 5.238B |
June 30, 2016 | 5.144B |
March 31, 2016 | 4.978B |
December 31, 2015 | 4.796B |
September 30, 2015 | 4.538B |
June 30, 2015 | 4.638B |
March 31, 2015 | 4.664B |
December 31, 2014 | 4.734B |
September 30, 2014 | 5.023B |
June 30, 2014 | 5.158B |
March 31, 2014 | 5.292B |
December 31, 2013 | 5.531B |
September 30, 2013 | 5.519B |
June 30, 2013 | 5.484B |
March 31, 2013 | 5.475B |
December 31, 2012 | 5.278B |
September 30, 2012 | 5.170B |
June 30, 2012 | 5.108B |
March 31, 2012 | 5.048B |
December 31, 2011 | 5.021B |
September 30, 2011 | 5.104B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.305B
Minimum
Jun 2019
9.313B
Maximum
Dec 2023
6.760B
Average
6.869B
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
Amgen Inc | 4.784B |
Madrigal Pharmaceuticals Inc | 272.35M |
Vertex Pharmaceuticals Inc | 3.163B |
Viking Therapeutics Inc | 63.81M |
Moderna Inc | 4.845B |